|1.||Shiraishi, Naoki: 3 articles (01/2015 - 01/2009)|
|2.||Kitamura, Kenichiro: 3 articles (01/2015 - 01/2009)|
|3.||Adachi, Masataka: 3 articles (01/2015 - 01/2009)|
|4.||Kakizoe, Yutaka: 3 articles (01/2015 - 01/2009)|
|5.||Miyoshi, Taku: 3 articles (01/2015 - 01/2009)|
|6.||Uchimura, Kohei: 2 articles (01/2015 - 07/2013)|
|7.||Mizumoto, Teruhiko: 2 articles (01/2015 - 07/2013)|
|8.||Sakai, Yoshiki: 2 articles (01/2015 - 07/2013)|
|9.||Hayata, Manabu: 2 articles (01/2015 - 07/2013)|
|10.||Ueda, Miki: 2 articles (01/2015 - 07/2013)|
01/01/1989 - "The favorable effect on survival time and rate in the early phase of these two severe experimental forms of pancreatitis may justify an evaluation of FOY-305 in a clinically controlled study."
08/01/1990 - "We conclude that lavage with camostate significantly improves the prognosis of severe necrotising pancreatitis in rats."
01/01/1989 - "FOY-305 showed a beneficial effect when given prophylactically or therapeutically at the beginning of the pancreatitis induced by a CDE diet, with no significant change in enzyme increase and degree of organ destruction. "
12/01/1996 - "Pretreatment with L-364,718, but not with camostat, caused significant improvement in signs of experimental pancreatitis based on tissue enzyme content and morphology. "
05/01/2007 - "Camostat mesilate, an orally available proteinase inhibitor, is clinically used for treatment of pancreatitis. "
03/01/2010 - "Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease."
03/01/2010 - "Camostat mesilate may serve as a therapeutic agent for patients with dyspepsia associated with mild pancreatic disease, who do not habitually drink alcohol."
04/01/2006 - "The aim of this study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against functional dyspepsia and to characterize patients with favorable responses. "
04/01/2006 - "Camostat mesilate is superior to famotidine for relieving epigastralgia in patients with functional dyspepsia. "
04/01/2006 - "Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?"
01/01/1994 - "The results of the present experiments clearly show that camostat can inhibit induction of hamster pancreatic ductal neoplasms when administered simultaneously with BOP."
07/01/1993 - "FOY-305 given intraperitoneally for 9 consecutive weeks inhibited the growth of the pre-existing dermal tumors. "
11/01/1983 - "There was no significant difference in the number of tumors per tumor-bearing mouse and the size of the tumors between mice treated with MCA and mice treated with MCA plus FOY-305."
11/01/1998 - "In conclusion, FOY-305 inhibited the invasion of tumor cells through interference with the u-PA activity of tumor cells, and this inhibitory activity was augmented by the combination with a MMP inhibitor."
07/01/1993 - "In contrast, the combined administration of FOY-305 and heparin suppressed tumor growth without any visible side effects. "
|4.||Diabetic Nephropathies (Diabetic Nephropathy)
04/01/1991 - "Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy."
01/01/1999 - "Effect of camostat mesilate on urinary protein excretion in three patients with advanced diabetic nephropathy."
08/01/1990 - "These effects of camostat mesilate may improve the prognosis of diabetic nephropathy."
08/01/1990 - "Effect of camostat mesilate for the treatment of advanced diabetic nephropathy."
01/01/1999 - "Camostat mesilate thus merits clinical trials in the treatment of nephrotic syndrome related to diabetic nephropathy."
|5.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/01/1993 - "Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma."
07/01/1993 - "There was a significant increase in well differentiated cancer cells in mice treated with FOY-305 and heparin in combination, suggesting that co-administration of FOY-305 and heparin may be useful for the treatment of squamous cell carcinoma."
05/01/1997 - "The half maximum inhibition concentrations of ONO-3403 toward BxPC-3 pancreatic carcinoma, T24 bladder carcinoma and A431 epidermoid carcinoma cells were 20-30 mu g/ml whereas those toward pancreatic carcinomas, PANC-1 and Mia PaCa-2, were 60-80 mu g/ml. Since FOY-305 has been shown to be effective in chemotherapy for human oral cancer, ONO-3403 is expected to be a more effective anticancer drug."
|2.||Protease Inhibitors (Protease Inhibitor)
|3.||FOY 305 (camostat)
|4.||Serine Proteases (Serine Protease)
|8.||ethyl N- allyl- N- (2- methyl- 3- (4- (4- amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate
|4.||Drug Therapy (Chemotherapy)